Multiple Myeloma

Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.

A panel of 4 experts on multiple myeloma

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

Research on CAR T-Cell Therapy in Multiple Myeloma

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Rafael Fonseca, MD;Surbhi Sidana, MD;Binod Dhakal, MD, MS;Adriana C. Rossi, MD

Isatuximab Combo Earns FDA Priority Review in Transplant-Ineligible NDMM

Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.

The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.

Russ Conroy

May 28th 2024

The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.

Despite increased education on autologous HCT, a lower rate of Black patients with multiple myeloma undergo treatment.

Sociodemographic Disparities in Auto-HCT Exist for Black Myeloma Population

Gina Mauro

Recent Bispecific Antibody Approvals in Relapsed/Refractory MM

Despite increased education on autologous HCT, a lower rate of Black patients with multiple myeloma undergo treatment.

Rafael Fonseca, MD;Surbhi Sidana, MD;Binod Dhakal, MD, MS;Adriana C. Rossi, MD

Key Takeaways from the CARTITUDE-1 and KarMMa Studies

The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

CAR T-Cell Therapy in Earlier Treatment Lines for Relapsed/Refractory Multiple Myeloma

Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.

Rafael Fonseca, MD;Surbhi Sidana, MD;Binod Dhakal, MD, MS;Adriana C. Rossi, MD

How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

APPs Focus on Education of Talquetamab Use and Administration in Multiple Myeloma

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

ONCOLOGY Staff

May 23rd 2024

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.

The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Advice for Community Oncologists Treating R/R Multiple Myeloma

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Monitoring Patients with Relapsed/Refractory Multiple Myeloma

An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Key Takeaways on Optimizing Multiple Myeloma Care

Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.

Caitlin Costello, MD, with the Oncology Brothers

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Maintenance Therapy in Patients with Multiple Myeloma

Caitlin Costello, MD, offers concluding remarks and guidance to healthcare providers on optimizing multiple myeloma patient care.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Monitoring Induction Therapy & MRD in Multiple Myeloma

A medical expert shares her treatment approach for a high-risk multiple myeloma patient, considering transplant eligibility, dose escalations, and maintenance therapy based on induction regimen and patient risk factors.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Tailoring Treatment for Patients with Multiple Myeloma

Caitlin Costello, MD, shares insights on the role of minimal residual disease (MRD) assessment in the multiple myeloma treatment process, including its impact on induction therapy and disease monitoring.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

The Role of Biomarkers in Diagnosing Multiple Myeloma

A medical expert discusses tailoring treatment strategies for standard-risk and high-risk multiple myeloma patients, considering patient characteristics and transplant eligibility when selecting treatment combinations.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD